⌕
Tarsus Pharmaceuticals Inc · TARS · Nasdaq
Tenet 41 · Weak
⇄ Compare
$75.46−3.15 (−4.01%)
At close: Oct 1, 2026, 4:00 PM ET

Tarsus Pharmaceuticals Inc · Statistics

Cheap or expensive, strong or fragile. Every ratio ranked against its sector peers — the number we score — with its own ten-year record shown beside it for context.

16
VALUE
Rich vs sector
premium price vs peers
55
QUALITY
Decent
mid-pack profitability
57
HEALTH
Stable
manageable balance sheet
35
GROWTH
Fair
steady, not spectacular

A decent business at a rich price for its sector: value 16, quality 55, health 57, growth 35, each a percentile within Healthcare.

On October 2, 2026 the Tenet Score and these statistics moved from the latest fiscal year to the trailing twelve months, for companies that file quarterly statements. Scores before October 2, 2026 were computed on fiscal-year figures.
Values are the trailing twelve months where a company files quarterly statements and the figure passes our check against the filings, with balance-sheet ratios from the most recent quarter; otherwise, or where a sector's figure is still under review, the latest fiscal year. Piotroski and the five-year growth rates are fiscal years. Each row names its period.track = where peers land, worse → better (direction-adjusted: right always means better)▏sector median● you are here▲ where today's value sits in the company's own ten fiscal years (context, not scored)hover any metric for its formula
16th pctilepremium price vs peers
Earnings yield (EBIT/EV)EBIT (operating income) for the latest fiscal year ÷ enterprise value on the current market cap (Greenblatt). The vendor's own earnings yield is net income to common ÷ market cap, a different figure.—excluded: no value on file for this company
P/E—excluded: no value on file for this company
P/B9.619th pctileMarket cap at the close of Oct 1, 2026 ÷ book equity at Jun 30, 2026 (most recent quarter)
P/FCF59.114th pctileown record too shortMarket cap at the close of Oct 1, 2026 ÷ free cash flow, TTM through Jun 30, 2026
EV / EBITDA—excluded: no value on file for this company
57th pctilemanageable balance sheet
Current ratio3.2048th pctileMost recent quarter, Jun 30, 2026
Quick ratioMost recent quarter: (Cash, short-term investments and receivables) ÷ current liabilities on the most recent quarter's balance sheet, as the data vendor builds it for that quarter. Its receivables include non-trade receivables, which Tenet's balance sheet shows inside other current assets.3.1254th pctileMost recent quarter, Jun 30, 2026
Net debt / EBITDA(Total debt − cash) ÷ EBITDA—excluded: negative EBITDA denominator
Interest coverage—excluded: operating income is negative, so coverage is not meaningful
Debt / equity0.2168th pctileMost recent quarter, Jun 30, 2026
55th pctilemid-pack profitability
ROIC−12%44th pctileown record too shortTTM through Jun 30, 2026
ROE−14%47th pctileTTM through Jun 30, 2026
Gross margin93.3%74th pctileTTM through Jun 30, 2026
Net margin−7.7%30th pctileown record too shortTTM through Jun 30, 2026
Income quality (CFO/NI)—excluded: net income is at or below zero, so cash flow over net income is not meaningful
Piotroski F5 / 956th pctileown record too shortFiscal 2025 (Dec 31, 2025)
Altman ZTrailing twelve months: Altman's bankruptcy-distance score as Tenet builds it: 1.2 × working capital ÷ total assets, plus 1.4 × retained earnings ÷ total assets, plus 3.3 × EBIT ÷ total assets, plus 0.6 × market cap at the close ÷ total liabilities, plus 1.0 × revenue ÷ total assets. EBIT and revenue are summed over the four most recent quarters and every balance is the most recent quarter's; higher is safer.8.077th pctileTTM through Jun 30, 2026
35th pctilesteady, not spectacular
Revenue CAGRThe yearly rate that compounds the oldest fiscal year's revenue into the latest one, over the true number of fiscal years between them (up to five).—excluded: no value on file for this company
EPS CAGR—excluded: no value on file for this company
FCF margin−4.9%35th pctileown record too shortFiscal 2025 (Dec 31, 2025)Fiscal 2025: held in Healthcare pending the TTM check
the receipts behind the numbers above
Greenblatt earnings yield—EBIT ÷ EV The vendor's "earningsYield" is NI ÷ market cap, which is not Greenblatt's formula.
ROIC−12%NOPAT ÷ invested capital The vendor's simple ROIC, not its tiny-base roic tag; withheld when a negative EBIT flips its sign.
Interest coverage— Guarded, not faked: we have no interest-expense figure on file for this company, so it's excluded from the ranking instead of rendered as garbage.
Percentiles computed nightly against 400 Healthcare peers from our ingested fundamentals DB · raw statements for corrected metrics. Direction-adjusted: for "lower is better" ratios (P/E, D/E…) the percentile is flipped so right always means better. The percentile is the stock's rank among sector peers, the number that is scored. The triangle marks where the current value (the trailing twelve months or the latest fiscal year, as its row names) sits in the company's own ten fiscal-year record, shown for context and never blended into the score. Computed 2026-10-02 · Not investment advice.
Methodology© 2026 Tenet Investing Inc. · Toronto, Canada

Data from Intrinio and Financial Modeling Prep.